특발성폐섬유증(IPF) 시장 : 치료법별, 지역별 - 시장 규모, 업계 동향, 기회 분석 및 예측(2026-2035년)

The Idiopathic Pulmonary Fibrosis (IPF) market is poised for significant growth over the next decade, reflecting a rising demand for effective treatments and advancements in medical technology. In 2025, the market is projected to generate approximately US$ 2,970.69 million, with estimates indicating that this figure will more than double to reach US$ 6,736.49 million by 2035. This substantial expansion corresponds to a compound annual growth rate (CAGR) of 9.4% during the period from 2026 to 2035, highlighting the strong momentum behind market growth.

The market is currently dominated by antifibrotic therapies, with Pirfenidone and Nintedanib being the cornerstone medications prescribed to slow the progression of IPF. These drugs have demonstrated clinical efficacy in reducing lung function decline, thereby improving patient outcomes and quality of life. Their widespread adoption across various regions underscores their vital role in the treatment landscape. However, the IPF market is undergoing a shift as research increasingly focuses on the development of targeted and novel therapies aimed at addressing the underlying mechanisms of the disease more precisely.

Noteworthy Market Developments

The idiopathic pulmonary fibrosis (IPF) market is characterized by a moderate to high level of concentration, with a relatively small number of key players controlling a significant share of the market. These leading companies have established strong footholds through robust product portfolios, extensive clinical expertise, and well-developed distribution networks. However, this concentration is gradually being challenged by increasing research and development efforts and a surge of innovation emerging from the biotechnology sector.

Among the major companies dominating the IPF market are well-established pharmaceutical giants such as Boehringer Ingelheim, Roche, AstraZeneca, and Bristol Myers Squibb. These firms have leveraged their extensive resources and experience to advance therapeutic development, conduct large-scale clinical trials, and secure regulatory approvals. In addition to these global leaders, smaller biotech companies like Pliant Therapeutics, FibroGen, and Vicore Pharma are gaining traction by focusing on innovative mechanisms of action and targeting specific pathways involved in the progression of IPF.

Currently, the market's therapeutic landscape is anchored by two primary products: Esbriet (Pirfenidone), marketed by Genentech, Inc., and Ofev (Nintedanib), developed by Boehringer Ingelheim Pharma GmbH & Co. KG. Both drugs have become standard-of-care treatments for IPF due to their proven efficacy in slowing disease progression and improving patients' quality of life. Their widespread adoption across various regions underscores their clinical importance and commercial success.

Core Growth Drivers

The Idiopathic Pulmonary Fibrosis (IPF) market is experiencing rapid expansion, largely driven by demographic shifts, particularly the increasing size of the geriatric population aged 60 and above. This age group is especially vulnerable to IPF, with approximately two-thirds of diagnosed patients falling into this category. As populations in key regions such as the United States, the European Union, and the Asia-Pacific continue to age, the prevalence of IPF is expected to rise correspondingly. This demographic trend significantly fuels demand for effective therapies, positioning the IPF market for robust growth characterized by a high compound annual growth rate (CAGR) over the coming years.

Emerging Opportunity Trends

The integration of Artificial Intelligence (AI) into the interpretation of High-Resolution Computed Tomography (HRCT) scans has brought about a significant advancement in the diagnosis of idiopathic pulmonary fibrosis (IPF), contributing to greater standardization and accuracy in clinical practice. Traditionally, diagnosing IPF through HRCT involves identifying complex lung patterns, such as honeycombing, which can be subtle and challenging for radiologists to detect consistently. Variability in human interpretation has often led to delays or misdiagnoses, affecting patient outcomes and treatment timeliness. However, the incorporation of AI algorithms into the diagnostic process is rapidly transforming this landscape by providing radiologists with powerful tools to enhance detection and improve diagnostic confidence.

Barriers to Optimization

The high cost of treatment poses a significant challenge that could potentially hamper the growth of the market. Expensive therapies often create barriers to access, especially for patients who lack comprehensive insurance coverage or live in regions with limited healthcare funding. When treatment costs are prohibitive, many patients may delay or forgo necessary care, which not only affects individual health outcomes but also constrains the overall market demand. This financial burden can be particularly acute for chronic or complex conditions requiring long-term medication, where cumulative expenses add up substantially over time.

Segment Breakdown

By Therapy

• Esbriet (Pirfenidone)
• Ofev (Nintedanib)
• Tipelukast
• Pamrevlumab
• KD025
• PRM 151
• GKT831
• Others

By Country

• The U.S.
• The UK
• France
• Germany
• Spain
• Italy
• Japan

Geography Breakdown

• North America continues to hold its position as the undisputed leader in the idiopathic pulmonary fibrosis (IPF) market, with the United States serving as the primary driving force behind this dominance. This leadership stems from multiple factors, notably a high diagnosis rate that reflects advanced healthcare infrastructure and widespread awareness of the disease. Additionally, the region benefits from a well-established reimbursement environment, which facilitates patient access to premium antifibrotic therapies that are essential for managing and slowing the progression of IPF.
• A comprehensive meta-analysis conducted by the National Institutes of Health (NIH) in 2025 highlights the significant regional prevalence of IPF in North America, estimating approximately 27.2 cases per 100,000 individuals. This prevalence rate markedly exceeds that found in other continents, underscoring the unique epidemiological characteristics of the region. The higher diagnosis rates, likely due to superior screening and reporting mechanisms, contribute to a larger patient pool and, consequently, a greater commercial opportunity for pharmaceutical companies specializing in IPF therapies.

Leading Market Participants

• Genentech, Inc.
• Boehringer Ingelheim Pharma GmbH, and Co. Kg
• MediciNova
• FibroGen, Inc.
• Kadmon Corporation, LLC
• Promedior
• Genkyotex
• CelgeneCorporation
• ProMetic LifeSciences
• Biogen, Inc.
• Merck and Co.
• Novartis
• Other Prominent Players

Table of Content

Chapter 1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

Chapter 2. Research Methodology

• 2.1. Qualitative Research
  • 2.1.1. Primary & Secondary Sources
• 2.2. Quantitative Research
  • 2.2.1. Primary & Secondary Sources
• 2.3. Breakdown of Primary Research Respondents, By Region
• 2.4. Assumption for the Study
• 2.5. Market Size Estimation
• 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Idiopathic Pulmonary Fibrosis (IPF) Market

Chapter 4. Global Idiopathic Pulmonary Fibrosis Market Overview

• 4.1. Idiopathic Pulmonary Fibrosis Overview
• 4.2. Industry Value Chain Analysis
  • 4.2.1. Formulation
  • 4.2.2. Processing & Packaging
  • 4.2.3. Distributor
  • 4.2.4. End users
• 4.3. Industry Outlook
  • 4.3.1. Epidemiology and Patient Population
    • 4.3.1.1. Key Findings
    • 4.3.1.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
    • 4.3.1.3. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
      • 4.3.1.3.1. United States
        • 4.3.1.3.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
        • 4.3.1.3.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
        • 4.3.1.3.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 4.3.1.3.2. EU5
        • 4.3.1.3.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
        • 4.3.1.3.2.2. UK
          • 4.3.1.3.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2.3. France
          • 4.3.1.3.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2.4. Germany
          • 4.3.1.3.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2.5. Spain
          • 4.3.1.3.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.2.6. Italy
          • 4.3.1.3.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
          • 4.3.1.3.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
          • 4.3.1.3.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
          • 4.3.1.3.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 4.3.1.3.3. Japan
        • 4.3.1.3.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
        • 4.3.1.3.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
        • 4.3.1.3.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
        • 4.3.1.3.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
  • 4.3.2. Current Treatment Practices
    • 4.3.2.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
    • 4.3.2.2. Patient Journey
  • 4.3.3. Unmet Needs
  • 4.3.4. Organizations contributing toward IPF
  • 4.3.5. KOL's Views: Idiopathic Pulmonary Fibrosis
  • 4.3.6. Case Reports
    • 4.3.6.1. Idiopathic Pulmonary Fibrosis: As case Discussion in the US
    • 4.3.6.2. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A Case Report of Europe
    • 4.3.6.3. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis - A Japanese Case Report
  • 4.3.7. Marketed Drugs
    • 4.3.7.1. Esbriet (Pirfenidone): Inter Mune Inc.
      • 4.3.7.1.1. Product Description
      • 4.3.7.1.2. Regulatory Milestones
      • 4.3.7.1.3. Clinical Development
      • 4.3.7.1.4. Ongoing Current Pipeline Activity
      • 4.3.7.1.5. Safety and efficacy
      • 4.3.7.1.6. Product Profile
    • 4.3.7.2. OFEV (Nintedanib): BoehringerIngelheim Pharma GmbH and Co. KG
      • 4.3.7.2.1. Regulatory Milestones
      • 4.3.7.2.2. Clinical Development
      • 4.3.7.2.3. Ongoing Current Pipeline Activity
      • 4.3.7.2.4. Safety and efficacy
      • 4.3.7.2.5. Product Profile
  • 4.3.8. Emerging Drugs
    • 4.3.8.1. Tipelukast: MediciNova
      • 4.3.8.1.1. Product Description
      • 4.3.8.1.2. Other Development Activities
      • 4.3.8.1.3. Clinical Development
      • 4.3.8.1.4. Clinical Trials Information
      • 4.3.8.1.5. Safety and Efficacy
      • 4.3.8.1.6. Product Profile
    • 4.3.8.2. Pamrevlumab: FibroGen
      • 4.3.8.2.1. Product Description
      • 4.3.8.2.2. Other Development Activities
      • 4.3.8.2.3. Clinical Development
      • 4.3.8.2.4. Clinical Trials Information
      • 4.3.8.2.5. Safety and Efficacy
      • 4.3.8.2.6. Product Profile
    • 4.3.8.3. KD025: Kadmon Corporation, LLCs
      • 4.3.8.3.1. Product Description
      • 4.3.8.3.2. Other Development Activities
      • 4.3.8.3.3. Clinical Development
      • 4.3.8.3.4. Clinical Trials Information
      • 4.3.8.3.5. Safety and Efficacy
      • 4.3.8.3.6. Product Profile

(**to be continued in final report)

• 4.4. PESTLE Analysis
• 4.5. Porter's Five Forces Analysis
  • 4.5.1. Bargaining Power of Suppliers
  • 4.5.2. Bargaining Power of Buyers
  • 4.5.3. Threat of Substitutes
  • 4.5.4. Threat of New Entrants
  • 4.5.5. Degree of Competition
• 4.6. Market Dynamics and Trends
  • 4.6.1. Growth Drivers
  • 4.6.2. Restraints
  • 4.6.3. Challenges
  • 4.6.4. Key Trends
• 4.7. Covid-19 Impact Assessment on Market Growth Trend
• 4.8. Market Growth and Outlook
  • 4.8.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030
  • 4.8.2. Price Trend Analysis
• 4.9. Competition Dashboard
  • 4.9.1. Market Concentration Rate
  • 4.9.2. Company Market Share Analysis (Value %), 2020
  • 4.9.3. Competitor Mapping

Chapter 5. Idiopathic Pulmonary Fibrosis Market Analysis, By Therapy

• 5.1. Key Insights
• 5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 5.2.1. Esbriet (Pirfenidone)
  • 5.2.2. Ofev (Nintedanib)
  • 5.2.3. Tipelukast
  • 5.2.4. Pamrevlumab
  • 5.2.5. KD025
  • 5.2.6. PRM 151
  • 5.2.7. GKT831
  • 5.2.8. Others

Chapter 6. Idiopathic Pulmonary Fibrosis Market Analysis, By Region/Country

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 6.2.1. The U.S.
  • 6.2.2. The UK
  • 6.2.3. France
  • 6.2.4. Germany
  • 6.2.5. Spain
  • 6.2.6. Italy
  • 6.2.7. Japan

Chapter 7. The U.S. Idiopathic Pulmonary Fibrosis Market Analysis

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 7.2.1. By Therapy

Chapter 8. The UK Idiopathic Pulmonary Fibrosis Market Analysis

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 8.2.1. By Therapy

Chapter 9. France Idiopathic Pulmonary Fibrosis Market Analysis

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 9.2.1. By Therapy

Chapter 10. Germany Idiopathic Pulmonary Fibrosis Market Analysis

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 10.2.1. By Therapy

Chapter 11. Italy Idiopathic Pulmonary Fibrosis Market Analysis

• 11.1. Key Insights
• 11.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 11.2.1. By Therapy

Chapter 12. Spain Idiopathic Pulmonary Fibrosis Market Analysis

• 12.1. Key Insights
• 12.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 12.2.1. By Therapy

Chapter 13. Japan Idiopathic Pulmonary Fibrosis Market Analysis

• 13.1. Key Insights
• 13.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
  • 13.2.1. By Therapy

Chapter 14. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 14.1. Genentech, Inc.
• 14.2. Boehringer Ingelheim Pharma GmbH and Co. Kg
• 14.3. MediciNova
• 14.4. FibroGen, Inc.
• 14.5. Kadmon Corporation, LLC
• 14.6. Promedior
• 14.7. Genkyotex
• 14.8. CelgeneCorporation
• 14.9. ProMetic LifeSciences
• 14.10. BioGen, Inc.
• 14.11. Merck and Co.
• 14.12. Novartis
• 14.13. Other prominent players